RDIF, Panacea Biotec partner to produce Sputnik V in India :

RDIF, Panacea Biotec partner to produce Sputnik V in India


RDIF, Panacea Biotec partner to produce Sputnik V in India
First batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Centre for quality control. Full-scale production of the vaccine is due to start soon
BusinessToday.In | May 24, 2021 | Updated 16:22 IST
Sputnik V vaccine got the emergency use authorisation in the country on April 12
Russia's sovereign wealth fund RDIF (Russian Direct Investment Fund) and homegrown pharma company Panacea Biotec have partnered to launch the Russian Sputnik V vaccine in India. The RDIF has already tied up with Dr Reddy's to produce the vaccine in India. Both have agreed to produce 100 million doses per year of Sputnik V.

Related Keywords

India , Russia , Russian , Kirill Dmitriev , Rajesh Jain , Gamaleya Centre , World Health Organisation , Russian Direct Investment Fund , Panacea Biotec , Biotec Dr Rajesh Jain , Panacia Biotec , Panacia Biotec Ties Up With Rdif , Rdif Panacia Biotec Tie Up , Sputnikv Production , Omestic Production Of Sputnik V , Covid 19 Vaccine , Sputnikv Vaccine , Covid 19 Vaccine In India , Sputnikv Production In India , Sputnikv Vaccine In India , , இந்தியா , ரஷ்யா , ரஷ்ய , ராஜேஷ் ஜெயின் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , ரஷ்ய நேரடி முதலீடு நிதி , சஞ்சீவி பயோடெக் , விட் தடுப்பூசி , விட் தடுப்பூசி இல் இந்தியா ,

© 2025 Vimarsana